Search Within

Myeloma

Formats
  1. Meeting Abstract (557)
  2. Journal Article (368)
  3. Review (37)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (7)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1016)
  2. Department of Medicine (1016)
  3. Hematologic Malignancies, Division of (1016)
  4. Hematologic Malignancies Research (669)
  5. Survivorship Research (374)
  6. Sloan Kettering Institute Postdocs (306)

More Groups

People
  1. Alexander Lesokhin (381)
  2. Hani Hassoun (339)
  3. Carl Landgren (336)
  4. Sham Mailankody (297)
  5. Malin Hultcrantz (274)
  6. Heather Landau (249)

More People

Years
  1. 2025 (28)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (317)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (86)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (24)

More Publications

Publishers
  1. American Society of Hematology (340)
  2. Elsevier Inc. (160)
  3. American Society of Clinical Oncology (88)
  4. Nature Publishing Group (87)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1016)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Duration of post-autologous hematopoietic cell transplant anemia and thrombocytopenia are associated with prolonged hospital length-of-stay for multiple myeloma patients
    Meeting Abstract

    Zheng-Lin, B.; Krishnamurthi, N.; Diamond, B.; Maclachlan, K. H.; Maura, F.; Landgren, O.; Chung, D. J.
    Blood (2020)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed to prior alkylator therapy-subgroup analysis
    Meeting Abstract

    Rodríguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in 55 patients (pts) with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD)-subgroup analysis
    Meeting Abstract

    Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of baseline and postinfusion biomarkers with safety and efficacy endpoints in patients treated with orvacabtagene autoleucel (orva-cel; JCARH125) in the phase 1/2 evolve study (NCT03430011)
    Meeting Abstract

    Piasecki, J.; Devries, T.; Radhakrishnan, A.; Li, Y.; Heipel, M.; Fox, B. A.; Beckett, V.; Stirner, M. C.; Conte, K.; Doerr, T.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Ramchandren, R.; Maris, M.; Lesokhin, A. M.; von Keudell, G. R.; Cheson, B. D.; Zonder, J.; Seymour, E. K.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) - health-related quality of life (HRQoL) analysis
    Meeting Abstract

    Oriol, A.; Richardson, P. G.; Mateos, M. V.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Infusion-related reactions (IRRs) in the DREAMM-2 Study of single-agent belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nooka, A.; Lee, H. C.; Badros, A. Z.; Voorhees, P.; Hultcrantz, M.; Karlin, L.; Arnulf, B.; Richardson, P. G.; Zhi, E.; Baron, J.; more...
    Blood (2020)

    Fulltext@MSK | Save